Wednesday, July 8, 2026

pharma · Cystic Fibrosis · Hepatitis C

Vertex Pharmaceuticals (Australia)

Vertex Pharmaceuticals (Australia) is a pharma organization headquartered in Boston, USA. Primary therapeutic focus areas include Cystic Fibrosis, Hepatitis C, Pain, Chronic Hepatitis C, Acute Pain. NovaPharmaNews links

Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
Status
Public
HQ
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
Founded
1989
Employees
6,304
Programs
159
Drugs
64
Patents
991
Clinical program

Exa-cel

Phase 3 · mab · Sickle Cell Disease

Exa-cel for Sickle Cell Disease is a Phase 3 program (mab) at Vertex Pharmaceuticals (Australia) Pty. with 1 ClinicalTrials.gov record(s).

Internal code VX21-CTX001-171

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Vertex Pharmaceuticals (Australia) Pty.
Phase
Phase 3
Modality
mab
Indication
Sickle Cell Disease
Status
terminated
Trials
1